Feedback / Questions
evixapodlin (GS-4224) - OmRx Oncology
https://www.businesswire.com/news/home/20250508700278/en/OmRx-Oncology-Initiates-Phase-2-Trial-of-Oral-PD-L1-Inhibitor-OX-4224-in-NSCLC
May 8, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next